Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib ExposureAndy C. Rawstron, Peter Hillmen, Andrew R. Pettitt et al.|Blood|2018Cited by 7